Related Experiment Video
Updated: May 4, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
Published on: June 9, 2021
Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia
Anja H Schiemann1, Neeti Paul, Remai Parker
1From the Institute of Fundamental Sciences, Massey University; and Department of Anaesthesia and Intensive Care, MidCentral Health, Palmerston North Hospital, Palmerston North, New Zealand.
Background:
Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder. More than 300 variants in the ryanodine receptor 1 (RYR1) have been associated with MH; however, only 31 have been identified as causative. To confirm a mutation in RYR1 as being causative for MH, segregation of the potential mutation in at least 2 unrelated families with MH susceptibility must be demonstrated and functional assays must show abnormal calcium release compared with wild-type RYR1.
Methods:
We used "Hot-spot" DNA screening to identify mutations in RYR1 in 3 New Zealand families. B-lymphoblastoid cells were used to compare the amount of calcium released on stimulation with 4-chloro-m-cresol between wild-type RYR1 cells and cells carrying the new variants in RYR1.
Results:
We identified a known RYR1 mutation (R2355W) in 2 families and another more recently identified (V2354M) mutation in another family. Both mutations segregated with MH susceptibility in the respective families. Cell lines carrying a mutation in RYR1 showed increased sensitivity to 4-chloro-m-cresol.
Conclusions:
We propose that R2355W is confirmed as being an MH-causative mutation and suggest that V2354M is a RYR1 mutation likely to cause MH.
More Related Videos
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Alterations in Muscle Tone lll
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cardiomyopathy I: Introduction and Classification
Ligand-Gated Ion Channel Receptor: Gating Mechanism

